A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
Phase 1
Completed
- Conditions
- Non-small-cell Lung Cancer
- Registration Number
- NCT00255489
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
- Provision of written informed consent
- Patients requiring low dose palliative thoracic irradiation to a field size of less than or equal to 150cm2
- Histologically or cytologically conformed non-small cell lung cancer
- Aged 18 or over
Exclusion Criteria
- Previous thoracic radiotherapy
- Any condition that may pre-dispose the patient to suffer an individual drug-relaged DLT (dose limiting toxicity) event
- Known hypersensitivity to any component of study medication
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To characterize the safety profile of ZD 1839 in these patients
- Secondary Outcome Measures
Name Time Method To measure the quality of life compared to baseline To measure the change in disease related symptoms compared to baseline
Trial Locations
- Locations (1)
Research Site
🇬🇧Leeds, United Kingdom